ArticleAmerican journal of cancer research2020

GD2 chimeric antigen receptor modified T cells in synergy with sub-toxic level of doxorubicin targeting osteosarcomas.

Monrat Chulanetra et al.PubMed ↗Full text ↗

No numbers read from the abstract.